Compare Neurocrine Biosciences Inc (NBIX) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs RLX Technology Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B), while RLX Technology Inc trades at $1.73 (market cap $2.10B). The key difference: Neurocrine Biosciences Inc is far larger — about 6.8× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.81% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and RLX Technology Inc for 35 Days on average.
| NBIX | RLX | |
|---|---|---|
Market Cap | $14.36B | $2.10B |
Volume | 1,237,180 | 1,079,706 |
Sector | Health | Consumer Staples |
52-Week High | $185.50 | $2.57 |
52-Week Low | $123.10 | $1.68 |
Typical Hold Time | 23 Days | 35 Days |
Enterprise Value | $14.37B | $832.26M |
Dividend Yield | — | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
RLX Technology trades at $1.735, up 0.29% with bearish technical signals despite recent 52-week lows. The company shows solid fundamentals with $3.62B revenue, 21.87% net margin, and attractive valuation at P/E 15.46 and P/B 0.91. Recent earnings missed expectations but international expansion drives growth, with 70% revenue now from overseas markets. Cash flow trends improved significantly from -$99M in 2025 to $881M projected for 2026.
RLX presents a value opportunity with discounted valuation and strong international growth, though technical weakness and earnings misses warrant caution. The single analyst coverage maintains Hold rating, reflecting uncertainty amid expansion execution risks and regulatory challenges in the e-vapor industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
